Consider a contraceptive that begins with mucus. In 2022, Organon signed a research collaboration and exclusive licensing agreement with Cirqle Biomedical, a company investigating whether reinforcing the cervix’s existing mucus barrier could impede sperm. The biology was unfamiliar territory for a business headline. The financial terms were easier to recognize: $10 million upfront, potential milestones of up to $360 million, and royalties.
Cirqle belongs to RH Capital’s portfolio. That pairing captures the fund’s proposition: a neglected health problem can contain both an interesting scientific question and an investable business. The trick is finding the right people to understand each. And then comes the less glamorous question: if the science works, who will actually get it?
- RH Capital backs early-stage women’s health businesses, from diagnostics to care delivery.
- Its second fund closed at $38.5 million in 2022.
- The investment team formed Foreground Capital in 2024 and retained management of both RH Capital funds.
A market had to be demonstrated
Elizabeth Bailey remembers an elementary uncertainty at the beginning: “Was there enough deal flow in women’s health?” That question, recalled in a 2024 interview, concerned the supply of investable companies. Before building a conventional venture firm, the team needed evidence that founders wanted its help and other investors would join it.
The experiment grew out of Rhia Ventures, the nonprofit established through the work of physician and philanthropist Ruth Shaber and Tara Health Foundation. RH Capital provided a for-profit investment arm. Foundations could help cultivate an unfamiliar market while entrepreneurs built businesses inside it. The structure gave an emerging category somewhere to develop.
Bailey and Stasia Obremskey co-founded and led the precursor funds. Their backgrounds help explain the approach. Bailey brought experience investing in early healthcare companies. Obremskey brought finance and operating work with healthcare organizations. Alice Zheng added clinical medicine, public health and consulting experience. Evaluating a care business calls for more than enthusiasm about an app.
What $43.5 million actually means
Fund I raised a reported $5 million in 2019. Fund II closed at $38.5 million in 2022, bringing reported combined assets under management to $43.5 million. These are pools of investment capital. They tell us about the resources entrusted to the managers; they do not tell us how much profit the firm earned.
The timing of the second close matters. Following the June 2022 Dobbs decision overturning Roe v. Wade, the firm reported raising another $10 million. Political upheaval increased interest among its backers. Tara Health Foundation, Skoll Foundation and other mission-oriented investors supported the fund. A threat to reproductive healthcare became a reason to commit more capital.
For entrepreneurs, the published parameters are practical: seed through Series A is the preferred stage, with initial checks typically between $500,000 and $1.5 million. Follow-on money is reserved. The fund can lead or join a syndicate. Companies can be based abroad, provided they have a near-term US market focus.
The patient belongs in the spreadsheet
RH Capital organizes impact around four ideas: innovation, access, affordability and systemic change. Read them as operating questions. Does a new test change care? Can a patient get it outside a specialist center? Does insurance cover the bill? Does the service address people whose needs have routinely been overlooked?
This is where its investment thesis becomes distinctive. A product’s technical sophistication cannot settle the question of who receives it. RH Capital explicitly considers Medicaid coverage, home-based services and culturally intentional care. Those choices affect distribution, reimbursement and the size of the reachable market. Health equity has consequences for the business plan.
“We do not seek concessionary returns.”RH Capital’s published FAQ
The distinction matters for founders. This is venture financing with financial expectations. Alongside capital, the firm describes help with strategy, fundraising and hiring, often through board participation. Clinical and technical specialists also inform diligence through its Women’s Health Innovation Council, created with Gates Foundation support. Expertise can make a complicated proposition easier for fellow investors to assess.
A portfolio with more than one front door
Look across the investments and the category becomes wonderfully untidy. Mae supports Black women through pregnancy and postpartum. Cayaba Care brings maternity services into homes. Other bets pursue diagnostics, devices and therapeutics. These are different ways of reaching the same broad goal: making care work for people whose circumstances the usual system handles poorly.
Cirqle illustrates the research end of that spectrum. Its 2022 agreement concerned an investigational candidate, with development work still ahead. A licensing deal is evidence of commercial interest, not proof that a treatment has reached patients. Ovia Health offers a different milestone: Labcorp acquired the digital family-health business in 2021. Acquisition terms were undisclosed.
For a founder comparing investors, the useful distinction is depth of fit. A general healthcare fund may offer a broader network; a specialist can spend more time on the clinical and commercial peculiarities of one field. SteelSky Ventures, for example, shares several women’s health portfolio interests. These firms can be alternatives in a fundraising search and partners in the same financing round. The better question is which investor understands the next obstacle: trial design, reimbursement, distribution or a missing lead investor. A recognizable logo on the cap table cannot answer that alone.
The structure changed with the market
Effective October 1, 2024, the team launched Foreground Capital, an independent firm that continued managing RH Capital Funds I and II. Rhia described a maturing market and an opportunity to attract larger pools of capital. The change concerned the organizational structure; existing funds and portfolio relationships continued.
The useful lesson is to match the financing to the job. Rhia’s separate 2026 Lifecycle Capital strategy proposes flexible instruments for enterprises facing thin margins or uneven cash flows. That acknowledges a boundary of venture finance: a valuable community service may lack the growth economics its investors require. Founders can copy RH Capital’s discipline by specifying the patient, payer and evidence needed before choosing their capital. An invention deserves a route into someone’s life.